Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00719901 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

NIH

Sponsor class

Stopped This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.

Conditions

Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions

DRUG: obatoclax mesylate
DRUG: bortezomib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)